Trial reportAmerican journal of respiratory and critical care medicine2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
Open access · greenAbstract readRandomized Controlled TrialClinical Trial, Phase III
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 3 pooled it
18.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2025Pooled it
- Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Pooled it
- Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.Annals of the American Thoracic Society · 2026Trial
- Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous forThe European respiratory journal · 2025Trial
- Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.The Lancet. Respiratory medicine · 2025Trial
- Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous forAnnals of the American Thoracic Society · 2023Trial
- Physiologically Based Pharmacokinetic Modeling of Elexacaftor-Tezacaftor-Ivacaftor in Adults and Pediatric People with Cystic Fibrosis: Exploring Brain Exposure and Neuropsychiatric Adverse Events.Clinical pharmacokinetics · 2026Article
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis.iScience · 2026Article
- SOLAR: a noninterventional study of outcomes over the long term of people with cystic fibrosis (CF) aged ≥6 years treated with elexacaftor/tezacaftor/ivacaftor using data from the French CF Registry.ERJ open research · 2026Article
- Pediatric hepatic laboratory reporting with CFTR modulators: a FAERS pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Effectiveness of elexacaftor/tezacaftor/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry.Pediatric research · 2026Article
- Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Sinonasal and Pulmonary Computed Tomography Images Before and After Triple-Combination Therapy in a Patient with Cystic Fibrosis Without ΔF508 Mutations.Diagnostics (Basel, Switzerland) · 2026Article
- Telehealth by Home Monitoring and Video Consultation for Children With Cystic Fibrosis: Qualitative and Quantitative Study.JMIR formative research · 2026Article
- Measurement of lung clearance index (LCIBMJ open respiratory research · 2026Observational
- ENHANCE: a community partnership charting the evolution of early-life cystic fibrosis disease manifestations in a new era of management.ERJ open research · 2026Article
- Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry.ERJ open research · 2026Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 15 institutions in 10 countries.
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin and.ORCID 0000-0002-4057-2199
Rossa BrughaGreat Ormond Street Hospital for Children, London, United Kingdom.
Silvia GartnerHospital Universitari Vall d'Hebron, Barcelona, Spain.
Julian LeggSouthampton Children's Hospital, Hampshire, United Kingdom.
Alexander MoellerUniversity Children's Hospital, Zurich, Switzerland.
Pedro Mondejar-LopezHospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain.
Dario PraisSchneider Children's Medical Center of Israel, Petah Tikva, Israel.
Tacjana PresslerCopenhagen University Hospital, Rigshospitalet, Denmark.
Felix RatjenThe Hospital for Sick Children, Toronto, Ontario, Canada.
Philippe ReixHôpital Femme Mère-Enfant, Hospices Civils de Lyon, Bron, France.
Paul D RobinsonThe Children's Hospital at Westmead, Sydney Children's Hospital Network, Sydney, Australia.
Hiran SelvaduraiThe Children's Hospital at Westmead, Sydney Children's Hospital Network, Sydney, Australia.
Florian StehlingUniversitätsklinikum Essen, Klinik für Kinderheilkunde III, Essen, Germany.
Neil AhluwaliaVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Emilio Arteaga-SolisVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Bote G BruinsmaVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Mark JenningsVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Samuel M MoskowitzVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Sabrina NoelVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Simon TianVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Tanya G WeinstockVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Pan WuVertex Pharmaceuticals Incorporated, Boston, Massachussetts.
Claire E WainwrightQueensland Children's Hospital, University of Queensland, Queensland, Australia.ORCID 0000-0001-8389-3809
Jane C DaviesNational Heart and Lung Institute, Imperial College London, London, United Kingdom.
Vertex Pharmaceuticals (United States) · USChildren's Hospital at Westmead · AUCopenhagen University Hospital · DKCystic Fibrosis Trust · GBEssen University Hospital · DEGreat Ormond Street Hospital · GBHôpital Femme Mère Enfant · FRHospital for Sick Children · CAHospital Universitario Virgen de la Arrixaca · ESHumboldt-Universität zu Berlin · DESouthampton Children's Hospital · GBTel Aviv University · ILThe University of Queensland · AUUniversity Children's Hospital Zurich · CHVall d'Hebron Hospital Universitari · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesChildChloride Channel AgonistsForced Expiratory VolumeHumansIndolesMutationPyrazolesPyridinesPyrrolidinesQuinolonesAminophenolsBenzodioxolesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorelexacaftorIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolonestezacaftorchildrencystic fibrosiselexacaftorivacaftortezacaftor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.